HOME > Business Wire > Article

Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
TOKYO--( BUSINESS WIRE )-- Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025.
Dr. Manabe will transition from his current role of Representative Director, Executive Chairperson and CEO to Representative Director and Executive Chairperson while Mr. Okuzawa will transition to Representative Director, President and CEO.
Under Dr. Manabe’s leadership, Daiichi Sankyo’s pioneering science and technology led to the resurgence of antibody drug conjugate (ADC) development within the pharmaceutical industry, leading to three of the largest licensing deals in history along with the approvals of ENHERTU® and DATROWAY®, two precision cancer medicines invented with Daiichi Sankyo’s DXd ADC Technology that are changing the way that metastatic breast cancer is treated.
Daiichi Sankyo’s five-year business plan (FY2021-2025) is progressing successfully with the rapid and global expansion of its oncology business. In order to ensure the solid achievement of FY2025 goals and to strengthen its management structure, Daiichi Sankyo’s Board of Directors appointed Mr. Okuzawa as the new CEO at the board meeting on January 31, 2025, based on the Nomination Committee’s report. This transition in April 2025 will occur as Daiichi Sankyo enters the final year of its current five-year business plan and it starts full scale preparation for the next five-year business plan (FY2026-2030).
Mr. Okuzawa joined Daiichi Sankyo in 1986 and has served as Representative Director, President and Chief Operating Officer (COO) since 2023. He also held the role of Chief Financial Officer (CFO) for two years and other senior leadership roles in international business, corporate strategy and human resources during his tenure at Daiichi Sankyo. Mr. Okuzawa graduated from Hitotsubashi University in Tokyo with a degree in Social Sciences. Mr. Okuzawa has 50,741 shares of the company as of September 30, 2024.
“Hiroyuki Okuzawa has played a pivotal role in advancing our current five-year business plan, driving unprecedented global growth for our company,” said Sunao Manabe. “Beyond his extensive experience as an international business leader and impressive accomplishments while serving as both COO and CFO at Daiichi Sankyo, Hiroyuki has been a key figure in transforming our corporate culture by exemplifying our core behaviors of inclusivity and diversity, collaboration and trust, and continuous development and growth. As the new CEO, I am confident that Hiroyuki will continue to provide strong leadership, propelling Daiichi Sankyo to the forefront of the global pharmaceutical industry by enhancing patient care worldwide through creating new medicines with our expertise in science and technology.”
“I am deeply honored to be the next CEO of Daiichi Sankyo and will follow Sunao Manabe’s exceptional leadership and unwavering commitment to patients and their families,” said Hiroyuki Okuzawa. “Building on this foundation, I will continue to leverage Daiichi Sankyo’s strengths in science and technology, and will continuously develop our talent globally. Under my leadership, we will create a 2035 vision and a next five-year business plan (FY2026-2030), continuing to enrich the quality of life worldwide.”
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit
www.daiichisankyo.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250130225103/en/
Contacts
Media Contacts:
Daiichi Sankyo Co., Ltd.
DS-PR_jp@daiichisankyo.com
Investor Relations Contact:
DaiichiSankyoIR_jp@daiichisankyo.com
Source: Daiichi Sankyo Company, Ltd
Business Wire
-
02/18 15:50 Nihon Global Growth Partners Issues Presentation Highlighting the Sign...
-
02/18 09:00 3D Investment Partners Issues Open Letter to Sapporo’s Board of Dire...
-
02/18 05:00 Kyocera to Establish "O-RU Alliance" to Advance 5G Open RAN Deployment...
-
02/18 05:00 Kyocera Develops AI-powered 5G Virtualized Base Station for the Teleco...
-
02/18 02:10 Mitsubishi Electric Researcher Elevated to IEEE Fellow, Class of 2025
-
02/17 07:01 FPT Establishes FPT BTP Park to Enhance SAP Business in Japan
-
02/17 06:40 Mitsubishi Electric Signs Agreement with HD Renewable Energy, Will Est...
-
02/15 08:18 ispace Completes Success 5 of Mission 2 Milestones
-
02/14 23:50 U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltini...
-
02/14 14:25 AESC Ranks Fourth in 2024 Global Energy Storage Cell Shipments Accordi...
-
02/14 09:12 Kao Corporation Discloses the "Board of Directors' Opinion on Sharehol...
-
02/14 08:43 MUFG Bank, Ltd. announces Risk-Adjusted Capital Ratio Based on the Bas...
-
02/14 02:10 Mitsubishi Electric and CP Group Join Forces in Support of Increased S...
-
02/13 17:00 Nexon Releases Earnings for Fourth Quarter and Full-Year 2024
-
02/13 16:00 INFINITI at the 2025 Canadian International Auto Show
-
02/13 16:00 EXEO Group Selects Tonkean as Premier Process Automation and Orchestra...
-
02/13 13:36 Women Entrepreneurs from ASEAN and Japan Drive Innovation, Sustainabil...
-
02/13 12:00 Fonon Technologies to Bring Cutting-Edge Laser Tech to NCMS Sustainmen...
-
02/13 02:00 Kao: Bioré UV Partners with Stray Kids for an Exciting New Global Sun...
-
02/13 01:00 Yamaha Motor: Consolidated Business Results Summary ‐ Full Fiscal Ye...
-
02/13 00:00 Brightcove Appoints Takayuki Tadokoro As Country Manager of Brightcove...
-
02/12 12:00 SBC Medical Group Holdings Announces its Purchase of Bitcoin
-
02/12 09:57 MUFG Bank, Ltd. announces Consolidated Summary Report for the nine mon...
-
02/12 06:30 JT Group Recognized on CDP’s “Climate Change A List” For the 6th...
-
02/12 01:30 ONLYONE TRAVEL, a Pioneer in Unique Custom-Made Journeys, Raises 100 M...
-
02/11 14:05 Robotics Research: How Asia, Europe and America Invest – IFR Reports
-
02/11 14:02 LRN Research Unveils Key Gaps and Opportunities in Global Ethics and C...
-
02/11 14:00 Oracle Red Bull Racing and 1Password Upgrade Security in Multi-Year Pa...
-
02/11 11:00 Telecentro Argentina Expands Use of Netcracker Digital OSS and Critica...
-
02/10 22:00 Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUD...